Loading…
Pandemic Treatment Access and Affordability Act of 2021
Legislative Progress
Introduced
January 28, 2021
Latest Action
March 22, 2021
Primary Sponsor
Janice D. SchakowskyDemocratic(IL)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
76pct
53d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Pandemic Treatment Access and Affordability Act of 2021 This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies. With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill. The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access. If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2022 · fourth_quarter · Copyright/Patent/Trademark
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
S. 4704, the Patent Examination and Quality Improvement Act of 2022 S. 4417, the PTAB Reform Act S. 4430, the Interagency Patent Coordination and Improvement Act of 2022. S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2022 · fourth_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID testing and vaccine distribution 5. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 6. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 7. Vaccine access under the American Rescue Plan 8. H.R. 7472, The Discounted Drugs for Clinical Trials Act, entire bill 9. S. 4053, The Discounted Drugs for Clinical Trials Act, entire bill 10. H.R. 7474, The Pharmaceutical Research and Transparency Act, entire bill 11. S. 4034, The Pharmaceutical Research and Transparency Act, entire bill 12. H.R. 7473, The Generic Substitution Non-Interference Act, entire bill 13. H.R. 7828, Price Relief, Innovation, and Competition for Essential Drugs Act (PRICED Act), entire bill 14. H.R. 5376, Inflation Reduction Act of 2022, provisions relating to premium subsidies under the Affordable Care Act 15. Proposed rulemaking under Section 1557 of the Affordable Care Act regarding Nondiscrimination in Health Programs and Activities 16. Implementation of the No Surprises Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
2022 · third_quarter · Copyright/Patent/Trademark
Patent Examination and Quality Improvement Act of 2022 S. 4417, the PTAB Reform Act S. 4430, the Interagency Patent Coordination and Improvement Act of 2022. S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2022 · third_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID testing and vaccine distribution 5. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 6. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 7. Vaccine access under the American Rescue Plan 8. H.R. 7472, The Discounted Drugs for Clinical Trials Act, entire bill 9. S. 4053, The Discounted Drugs for Clinical Trials Act, entire bill 10. H.R. 7474, The Pharmaceutical Research and Transparency Act, entire bill 11. S. 4034, The Pharmaceutical Research and Transparency Act, entire bill 12. H.R. 7473, The Generic Substitution Non-Interference Act, entire bill 13. H.R. 7828, Price Relief, Innovation, and Competition for Essential Drugs Act (PRICED Act), entire bill 14. H.R. 5376, Inflation Reduction Act of 2022, provisions relating to premium subsidies under the Affordable Care Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · second_quarter · Copyright/Patent/Trademark
S. 4417, the PTAB Reform Act S. 4430, the Interagency Patent Coordination and Improvement Act of 2022. S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2022 · second_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID testing and vaccine distribution 5. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 6. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 7. Vaccine access under the American Rescue Plan 8. H.R. 7472, The Discounted Drugs for Clinical Trials Act, entire bill 9. S. 4053, The Discounted Drugs for Clinical Trials Act, entire bill 10. H.R. 7474, The Pharmaceutical Research and Transparency Act, entire bill 11. S. 4034, The Pharmaceutical Research and Transparency Act, entire bill 12. H.R. 7473, The Generic Substitution Non-Interference Act, entire bill 13. H.R. 7828, Price Relief, Innovation, and Competition for Essential Drugs Act (PRICED Act), entire bill
Client expense: $80,000 · Firm income: Not reported
2022 · first_quarter · Copyright/Patent/Trademark
S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
2022 · first_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID testing and vaccine distribution 5. Extension of COBRA coverage during the COVID-19 pandemic 6. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 7. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 8. Vaccine access under the American Rescue Plan
Client expense: $80,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Copyright/Patent/Trademark
H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021 - Provisions related to patent settlements H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to intellectual property H.R. 728: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights H.R. 1629: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs H.R. 1857: Protecting Access to Safe and Effective Medicines Act of 2021 - Provisions related to FDA policy and exclusivity H.R. 2148: Prescription Drug Price Relief Act of 2021 - Provisions related to prescription drug pricing and march-in rights H.R. 2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - Provisions related to intellectual property and patents H.R. 2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Provisions related to patent infringement H.R. 2891: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 187: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights S. 250: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs S. 415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity - Provisions related to FDA policy and exclusivity S. 1428: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 1435: Affordable Prescriptions for Patients Act of 2021 - Provisions related to intellectual property and patents S. 2774: Pride in Patent Ownership Act - Provisions related to patent transparency S. 2891: Restoring the America Invents Act - Provisions related to USPTO policy Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues
2021 · fourth_quarter · Copyright/Patent/Trademark
H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021 - Provisions related to patent settlements H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to intellectual property H.R. 728: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights H.R. 1629: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs H.R. 1857: Protecting Access to Safe and Effective Medicines Act of 2021 - Provisions related to FDA policy and exclusivity H.R. 2148: Prescription Drug Price Relief Act of 2021 - Provisions related to prescription drug pricing and march-in rights H.R. 2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - Provisions related to intellectual property and patents H.R. 2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Provisions related to patent infringement H.R. 2891: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 187: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights S. 250: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs S. 415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity - Provisions related to FDA policy and exclusivity S. 1428: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 1435: Affordable Prescriptions for Patients Act of 2021 - Provisions related to intellectual property and patents S. 2774: Pride in Patent Ownership Act - Provisions related to patent transparency S. 2891: Restoring the America Invents Act - Provisions related to USPTO policy Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues
2021 · fourth_quarter · Copyright/Patent/Trademark
H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: $10,000 · Firm income: Not reported
2021 · fourth_quarter · Copyright/Patent/Trademark
H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021 - Provisions related to patent settlements H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to intellectual property H.R. 728: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights H.R. 1629: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs H.R. 1857: Protecting Access to Safe and Effective Medicines Act of 2021 - Provisions related to FDA policy and exclusivity H.R. 2148: Prescription Drug Price Relief Act of 2021 - Provisions related to prescription drug pricing and march-in rights H.R. 2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - Provisions related to intellectual property and patents H.R. 2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Provisions related to patent infringement H.R. 2891: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 187: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights S. 250: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs S. 415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity - Provisions related to FDA policy and exclusivity S. 1428: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements S. 1435: Affordable Prescriptions for Patients Act of 2021 - Provisions related to intellectual property and patents S. 2774: Pride in Patent Ownership Act - Provisions related to patent transparency S. 2891: Restoring the America Invents Act - Provisions related to USPTO policy Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues
2021 · fourth_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID testing and vaccine distribution 5. Extension of COBRA coverage during the COVID-19 pandemic 6. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 7. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 8. Vaccine access under the American Rescue Plan
Client expense: $70,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)
2021 · third_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID vaccine distribution 5. Extension of COBRA coverage during the COVID-19 pandemic 6. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 7. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 8. Vaccine Access under the American Rescue Plan
Client expense: $80,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA)
2021 · third_quarter · Copyright/Patent/Trademark
S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5374, the SHOP SAFE Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to draft legislation on the Digital Millennium Copyright Act (DMCA) Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: $10,000 · Firm income: Not reported
2021 · second_quarter · Health Issues
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 1978, Protecting Seniors Through Immunization Act of 2021 H.R. 2061, Advancing Emergency Preparedness Through One Health Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 2076, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. H.R. 8920/S. 4760, (116th Congress) The Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2020 S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; Package inserts and labeling issues; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
2021 · second_quarter · Copyright/Patent/Trademark
S. 1260, the United States Innovation and Competition Act of 2021 H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to draft legislation on the Digital Millennium Copyright Act (DMCA) Issues related to the WTO TRIPs Waiver Request Issues related to the US Court of Appeals for the Federal Circuit Nomination
Client expense: $10,000 · Firm income: Not reported
2021 · second_quarter · Health Issues
1. Patient Protection and Affordable Health Care Act, implementation of provisions regarding high risk insurance pools, implementation of state based health exchanges, eligibility for health insurance premium subsidies, cost sharing subsidies, proposals for special enrollment period 2. Stabilization of Affordable Care Act insurance marketplaces 3. Administration proposals on prescription drug pricing 4. Administration proposals for COVID vaccine distribution 5. Extension of COBRA coverage during the COVID-19 pandemic 6. S. 779, Protecting Americans with Pre-Existing Conditions Act of 2021, entire bill 7. H.R. 597, Pandemic Treatment Access and Affordability Act of 2021, entire bill 8. Vaccine Access under the American Rescue Plan
Client expense: $80,000 · Firm income: Not reported
Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA)
2021 · first_quarter · Health Issues
H.R. 349: Coronavirus Vaccine and Therapeutic Development Act of 2021 - Provisions related to manufacturing of COVID-19 treatments and vaccines H.R. 387: Vaccinate More Americans Act of 2021 - Provisions related to COVID-19 vaccines H.R. 467: Protecting Patient Access to Lifesaving COVID-19 Drugs Act of 2021 - Provisions related to COVID-19 treatments H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to drug pricing and COVID-19 vaccines and treatments H.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process H.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation H.R. 853: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B drug discount program H.R. 1391: Taxpayer Research and Coronavirus Knowledge Act of 2021 - Provisions related to COVID-19 health research H.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products H.R. 2181: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. - Provisions related to prescription drug importation H.R. 2347: To amend title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program, and for other purposes. - Provisions related to COVID-19 vaccines S. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process S. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products S. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation S. 562: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions - Provisions related to citizen petitions S. 670: To amend the Federal Food, Drug, and Cosmetic Act to accelerate development of therapies across the spectrum of rare diseases and conditions and facilitate patient access to such therapies, and for other purposes. - Provisions related to FDA policy and health research S. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. - Provisions related to 340B drug discount program S. 898: A bill to require reporting regarding certain drug price increases, and for other purposes. - Provisions related to prescription drug pricing transparency S. 917: A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages S. 920: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals - Provisions related to prescription drug importation HHS PREP Act declaration relating to COVID-19 Drug cost and pricing policy issues Drug importation policy issues Expanded access policy issues Supply chain policy issues Real world evidence policy issues Regenerative medicine policy issues Antimicrobial resistance (AMR) policy issues FDA modernization policy issues 340B drug discount program policy issues Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues Defense Production Act (DPA) policy issues Final Rule; Importation of Prescription Drugs Executive Order 14017, Americas Supply Chains (February 24, 2021) Executive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020) Interim Final Rule with comment period; Most Favored Nation (MFN) Model Executive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020) Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Nomination of HHS Secretary Xavier Becerra Nominaton of USTR Katherine Tai Nomination of OMB Deputy Director Shalanda Young Nomination of CMS Administrator Chiquita Brooks-LaSure
2021 · first_quarter · Copyright/Patent/Trademark
H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021 - Provisions related to patent settlements H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to intellectual property H.R. 728: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights H.R. 1629: To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs, and for other purposes - Provisions related to FDA policy and orphan drugs H.R. 1857: To amend the Federal Food, Drug, and Cosmetic Act to clarify the meaning of a new chemical entity - Provisions related to FDA policy and exclusivity H.R. 2148: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries - Provisions related to prescription drug pricing and march-in rights S. 187: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights S. 250: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs S. 415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity - Provisions related to FDA policy and exclusivity S. 908: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries - Provisions related to prescription drug pricing and intellectual property S. 917: A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues
2021 · first_quarter · Pharmacy
H.R.597 - Pandemic Treatment Access and Affordability Act of 2021 - in support of bill. S.833 - Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021 - in support of bill. Issues raised in H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, from the last Congress and modifications to same. Lobbied in support of a temporary waiver of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement for the COVID-19 vaccine.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
2021 · first_quarter · Health Issues
H.R. 597, Pandemic Treatment Access and Affordability Act of 2021 H.R. 959, Black Maternal Health Momnibus Act of 2021 H.R. 1319, American Rescue Plan Act of 2021, medical provisions H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2061, To establish an interagency One Health Program, and for other purposes H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 H.R. 133 (116th Congress) Consolidated Appropriations Act of 2021 AMP cap provision H.R. 4100/S. 1712 (116th Congress) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. S. 1895 (116th Congress) Lower Health Care Costs Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Maternal Health; Cost and value of medicines; Vaccines; HIV, PrEP provisions; COVID-19 vaccines; COVID-19 vaccine funding; COVID-19 therapeutics coverage issues; Vaccines catch up; Vaccine provisions; Vaccine Issues, including access and pandemic-related policy; General pharmaceutical issues; Package inserts and labeling issues; Average Manufacture Price (AMP) cap; Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2022 Budget and Appropriations Legislation; Intellectual property; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; One Health Issues; Rural Broadband Issues.
Client expense: $3,590,000 · Firm income: Not reported
2021 · first_quarter · Copyright/Patent/Trademark
H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to draft legislation on the Digital Millennium Copyright Act (DMCA) Issues related to the WTO TRIPs Waiver Request Issues related to general IP policy
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2021 · first_quarter · Health Issues
H.R. 5: Equality Act H.R. 349: Coronavirus Vaccine and Therapeutic Development Act of 2021 - Provisions related to manufacturing of COVID-19 treatments and vaccines H.R. 387: Vaccinate More Americans Act of 2021 - Provisions related to COVID-19 vaccines H.R. 467: Protecting Patient Access to Lifesaving COVID-19 Drugs Act of 2021 - Provisions related to COVID-19 treatments H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to drug pricing and COVID-19 vaccines and treatments H.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process H.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation H.R. 853: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B drug discount program H.R. 1391: Taxpayer Research and Coronavirus Knowledge Act of 2021 - Provisions related to COVID-19 health research H.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products H.R. 2078: Social and Economic Equity Promotion Act - CBO analyses H.R. 2181: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals - Provisions related to prescription drug importation H.R. 2347: To amend title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program, and for other purposes - Provisions related to COVID-19 vaccines S. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process S. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products S. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation S. 562: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions - Provisions related to citizen petitions S. 670: To amend the Federal Food, Drug, and Cosmetic Act to accelerate development of therapies across the spectrum of rare diseases and conditions and facilitate patient access to such therapies, and for other purposes - Provisions related to FDA policy and health research S. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes - Provisions related to 340B drug discount program S. 898: A bill to require reporting regarding certain drug price increases, and for other purposes - Provisions related to prescription drug pricing transparency S. 917: A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages S. 920: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals - Provisions related to prescription drug importation HHS PREP Act declaration relating to COVID-19 Drug cost and pricing policy issues Drug importation policy issues Expanded access policy issues Supply chain policy issues Real world evidence policy issues Regenerative medicine policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues FDA modernization policy issues 340B drug discount program policy issues Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues Defense Production Act (DPA) policy issues Final Rule; Importation of Prescription Drugs Executive Order 14017, Americas Supply Chains (February 24, 2021) Executive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020) Interim Final Rule with comment period; Most Favored Nation (MFN) Model Executive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020) Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Nomination of HHS Secretary Xavier Becerra Nominaton of USTR Katherine Tai Nomination of HHS Assistant Secretary Rachel Levine Nomination of OMB Deputy Director Shalanda Young Nomination of CMS Administrator Chiquita Brooks-LaSure
2021 · first_quarter · Copyright/Patent/Trademark
H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021 - Provisions related to patent settlements H.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to intellectual property H.R. 728: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights H.R. 1857: To amend the Federal Food, Drug, and Cosmetic Act to clarify the meaning of a new chemical entity - Provisions related to FDA policy and exclusivity H.R. 2148: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries - Provisions related to prescription drug pricing and march-in rights S. 187: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights S. 250: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs S. 415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity - Provisions related to FDA policy and exclusivity S. 908: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries - Provisions related to prescription drug pricing and intellectual property S. 917: A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages Biopharmaceutical innovation and patent policy issues Bayh-Dole march-in rights policy issues
| House |
| Referred to |
| January 28, 2021 |
| Democratic |
| MS |
| Betty McCollum | Democratic | MN |
| Chellie Pingree | Democratic | ME |
| David E. Price | Democratic | NC |
| Dina Titus | Democratic | NV |
| Dwight Evans | Democratic | PA |
| Eleanor Holmes Norton | Democratic | DC |
| Jahana Hayes | Democratic | CT |
| Jamie Raskin | Democratic | MD |
| Judy Chu | Democratic | CA |
| Lloyd Doggett | Democratic | TX |
| Mark DeSaulnier | Democratic | CA |
| Mark Pocan | Democratic | WI |
| Mary Gay Scanlon | Democratic | PA |
| Michael F. Q. San Nicolas | Democratic | GU |
| Peter A. DeFazio | Democratic | OR |
| Peter Welch | Democratic | VT |
| Pramila Jayapal | Democratic | WA |
| Raúl M. Grijalva | Democratic | AZ |
| Ro Khanna | Democratic | CA |
| Rosa L. DeLauro | Democratic | CT |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Steve Cohen | Democratic | TN |
Government targets: Administration on Aging, Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $1,000,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Client expense: $1,000,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $7,160,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $1,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $1,800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $1,800,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $8,540,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Client expense: $8,540,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)